Rheumatoid Arthritis Clinical Trial
— P @ WorkOfficial title:
Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis.
NCT number | NCT02362074 |
Other study ID # | P14-455 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 21, 2015 |
Est. completion date | March 6, 2020 |
Verified date | February 2021 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to describe the impact of treatment with adalimumab on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
Status | Completed |
Enrollment | 401 |
Est. completion date | March 6, 2020 |
Est. primary completion date | March 6, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. Subjects with moderate to severe RA for whom the physician has decided to initiate treatment with adalimumab 2. Adult male or female = 18 years old that has been newly prescribed adalimumab therapy according to the local product label and are with PROGRESS 3. Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB 4. Subject is able to give written patient authorization and is willing to comply with the requirements of this study protocol. Exclusion Criteria: 1. Subject cannot or will not sign a patient authorization 2. Subject with a known hypersensitivity to Adalimumab, or any of its components 3. Presence of any condition that, in the opinion of the treating physician, prohibits the subject from participating in the study or obscures the assessment of the treatment of RA 4. Subjects currently participating in an investigational clinical trial 5. Subjects treated with >1 prior biologic disease-modifying antirheumatic drugs (DMARDs) for RA. Any prior treatment with adalimumab is prohibited 6. Subjects previously treated with targeted synthetic disease modifying agent. |
Country | Name | City | State |
---|---|---|---|
Canada | Waterside Clinique /ID# 134190 | Barrie | Ontario |
Canada | Drs Nalin and Vandana Ahluwali /ID# 136485 | Brampton | Ontario |
Canada | Dr. Sanjay Dixit Medicine Professional Corporation /ID# 136486 | Burlington | Ontario |
Canada | Pont, Cranbrook, BC, CA /ID# 134511 | Cranbrook | British Columbia |
Canada | Dr. Chrisotomor Kouroukis & Dr /ID# 151189 | Dundas | Ontario |
Canada | Adachi Medicine Prof. Corp /ID# 152538 | Hamilton | Ontario |
Canada | West Mountain Medical Center /ID# 134832 | Hamilton | Ontario |
Canada | Brandusa Florica Med Prof Corp /ID# 134829 | Mississauga | Ontario |
Canada | Credit Valley Rheumatology /ID# 134834 | Mississauga | Ontario |
Canada | Dr. Martin M.S. Lee Med Prof C /ID# 138333 | Mississauga | Ontario |
Canada | Montgomery, Mississauga, CA /ID# 136943 | Mississauga | Ontario |
Canada | Institut de Rhum. de Montreal /ID# 135289 | Montreal | Quebec |
Canada | Jewish General Hospital /ID# 204168 | Montreal | Quebec |
Canada | PSS Medical Inc. /ID# 134193 | Montreal | Quebec |
Canada | Clinique de Rhumatologie de Montréal /ID# 162186 | Montréal | Quebec |
Canada | Rajwinder S. Dhillon Medicine /ID# 147756 | Niagara Falls | Ontario |
Canada | Capital North Therapeutics Res /ID# 134835 | Ottawa | Ontario |
Canada | Setty, Owen Sound, CA /ID# 134189 | Owen Sound | Ontario |
Canada | Drs. M & W Teo Inc. /ID# 148641 | Penticton | British Columbia |
Canada | The Medical Centre /ID# 134833 | Peterborough | Ontario |
Canada | Chuq - Chul /Id# 137054 | Quebec | |
Canada | Ctr. de Rheum de l'est du QC /ID# 135410 | Rimouski | Quebec |
Canada | Dr. Latha Naik /ID# 135813 | Saskatoon | Saskatchewan |
Canada | Nexus Clinical Research /ID# 135411 | St. John's | Newfoundland and Labrador |
Canada | St. Clare's Mercy Hospital /ID# 136737 | St. John's | Newfoundland and Labrador |
Canada | Dr. Juris Lazovskis Inc. /ID# 134510 | Sydney | Nova Scotia |
Canada | Dr. Samuel K Silverberg /ID# 136496 | Toronto | Ontario |
Canada | Involved Medicine /ID# 163880 | Toronto | Ontario |
Canada | Kur, Vancouver, CA /ID# 135371 | Vancouver | British Columbia |
Canada | The Arthritis Research Center /ID# 147466 | Vancouver | British Columbia |
Canada | Rheum Disease Ctr of Montreal /ID# 135372 | Westmount | Quebec |
Canada | Manitoba Clinic /ID# 134830 | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Rheumatoid Arthritis-Work Instability Scale (RA-WIS) | This is patient-reported assessment on the impact of adalimumab on the work status of RA patients. | From Month 0 to Month 6 | |
Primary | Change in Financial Loss | This is patient reported assessment of financial burden of RA. | From Month 0 to Month 6 | |
Secondary | Change in Rheumatoid Arthritis-Work Instability (RA-WIS) | This is patient-reported assessment on the impact of adalimumab on the work status of RA patients. | From Month 0 to Month 12, 18 and 24 | |
Secondary | Change in the Financial Loss | This is patient reported assessment of financial burden of RA. | From Month 0 to Month 12, 18 and 24 | |
Secondary | Change in patient pain | Pain is assessed using Visual Analogue Scale (VAS) | From Month 0 to Month 24 | |
Secondary | Change in Tender Joint Count (TJC) | This is assessed by the physician. | From Month 0 to Month 24 | |
Secondary | Change in Disease Activity Score (DAS) 28 | Disease activity assessment is done by the physician. | From Month 0 to Month 24 | |
Secondary | Change in patient assessment of Global Disease Activity | It is assessed using VAS. | From Month 0 to Month 24 | |
Secondary | Change in Swollen Joint Count (SJC) | This is assessed by the physician. | From Month 0 to Month 24 | |
Secondary | Change in physician's assessment of Global Disease Activity | It is assessed using VAS. | From Month 0 to Month 24 | |
Secondary | Change in Health Assessment Questionnaire (HAQ) | This is patient reported functional assessment. | From Month 0 to Month 24 | |
Secondary | Change in c-reactive protein (CRP)/erythrocyte sedimentation rate (ESR) | CRP/ESR values are measured as an inflammatory parameter. Low CRP and ESR values mean less inflammation. | From Month 0 to Month 24 | |
Secondary | Rate of Remission per Disease Activity Scale (DAS) 28 | The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score less than 2.6 indicates clinical remission. | From Month 0 to Month 24 | |
Secondary | Rate of Achieving Low Disease Activity (LDA) per Disease Activity Score (DAS) 28 | The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores range from 0 to 10 with LDA defined as a score from 2.6 to < 3.2. | From Month 0 to Month 24 | |
Secondary | Rate of Remission Per Clinical Disease Activity Index (CDAI) | The CDAI is used to evaluate disease activity in patients with Rheumatoid Arthritis. | From Month 0 to Month 24 | |
Secondary | Rate of Achieving Low Disease Activity (LDA) per CDAI | The CDAI is a composite index for assessing disease activity. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to = 10. | From Month 0 to Month 24 | |
Secondary | Rate of Remission per Simplified Disease Activity Index (SDAI) | The SDAI is a validated measure of rheumatoid arthritis disease activity. Scores on the SDAI range from 0 to 86 with a SDAI score =3.3 indicating clinical remission. | From Month 0 to Month 24 | |
Secondary | Rate of Achieving Low Disease Activity (LDA) per SDAI | The SDAI is a validated measure of rheumatoid arthritis disease activity. Scores on the SDAI range from 0 to 86 with a SDAI score <11 indicating LDA. | From Month 0 to Month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |